Filing Details

Accession Number:
0001209191-18-025031
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-04-16 17:31:13
Reporting Period:
2018-04-12
Accepted Time:
2018-04-16 17:31:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178879 Amicus Therapeutics Inc FOLD Pharmaceutical Preparations (2834) 200422823
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1601896 Jay Barth C/O Amicus Therapeutics, Inc.
1 Cedar Brook Drive
Cranbury NJ 08512
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-04-12 5,000 $2.29 90,409 No 4 M Direct
Common Stock Disposition 2018-04-12 5,000 $14.72 85,409 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (right to buy) Disposition 2018-04-12 5,000 $0.00 5,000 $2.29
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
100,000 2024-03-03 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 125 Indirect By Daughter
Footnotes
  1. The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2017.
  2. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.61 to $14.86. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. All of the options were fully vested and exercisable as of April 12, 2018.